Analysts See $0.34 EPS for Supernus Pharmaceuticals, Inc. (SUPN); Permian Basin Royalty Trust (PBT) Shorts Increased By 10.7%

April 15, 2018 - By mmahotstuff

Analysts expect Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) to report $0.34 EPS on May, 8.They anticipate $0.15 EPS change or 78.95% from last quarter’s $0.19 EPS. SUPN’s profit would be $17.52M giving it 33.27 P/E if the $0.34 EPS is correct. After having $0.44 EPS previously, Supernus Pharmaceuticals, Inc.’s analysts see -22.73% EPS growth. The stock decreased 1.74% or $0.8 during the last trading session, reaching $45.25. About 380,210 shares traded. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has risen 46.59% since April 15, 2017 and is uptrending. It has outperformed by 35.04% the S&P500.

Permian Basin Royalty Trust (NYSE:PBT) had an increase of 10.7% in short interest. PBT’s SI was 251,400 shares in April as released by FINRA. Its up 10.7% from 227,100 shares previously. With 115,500 avg volume, 2 days are for Permian Basin Royalty Trust (NYSE:PBT)’s short sellers to cover PBT’s short positions. The SI to Permian Basin Royalty Trust’s float is 0.57%. The stock decreased 0.10% or $0.01 during the last trading session, reaching $9.7. About 123,845 shares traded or 26.33% up from the average. Permian Basin Royalty Trust (NYSE:PBT) has risen 5.95% since April 15, 2017 and is uptrending. It has underperformed by 5.60% the S&P500.

Investors sentiment increased to 0.96 in Q4 2017. Its up 0.12, from 0.84 in 2017Q3. It improved, as 9 investors sold Permian Basin Royalty Trust shares while 14 reduced holdings. 10 funds opened positions while 12 raised stakes. 4.55 million shares or 3.23% more from 4.41 million shares in 2017Q3 were reported. Moreover, Catawba Mgmt Va has 0.03% invested in Permian Basin Royalty Trust (NYSE:PBT) for 17,501 shares. Susquehanna Int Gp Llp owns 41,089 shares. Citadel Advsr Limited Liability Corporation invested in 0% or 99,259 shares. Mraz Amerine Associate reported 0.2% stake. Beck Mack & Oliver Ltd Llc accumulated 16,400 shares. Blair William Co Il reported 17,500 shares stake. Pnc Financial Serv Grp holds 12,386 shares or 0% of its portfolio. The North Carolina-based Carroll Associate has invested 0% in Permian Basin Royalty Trust (NYSE:PBT). Hancock Communications holds 0.01% of its portfolio in Permian Basin Royalty Trust (NYSE:PBT) for 25,145 shares. Price Michael F, New York-based fund reported 23,841 shares. Diligent Limited Liability owns 10,200 shares for 0.06% of their portfolio. Wells Fargo & Mn holds 25,130 shares or 0% of its portfolio. Cap Invest Advisors Ltd reported 0.03% stake. Foundation Res Management Incorporated holds 1.09M shares. Fruth Mngmt reported 19,900 shares stake.

Permian Basin Royalty Trust, an express trust, holds overriding royalty interests in various gas and oil properties in the United States. The company has market cap of $452.11 million. The firm owns a 75% net overriding royalty interest in the Waddell Ranch properties comprising Dune, Judkins, McKnight, Tubb, University-Waddell, and Waddell fields located in Crane County, Texas. It has a 15.42 P/E ratio. As of December 31, 2016, its Waddell Ranch properties contained 349 net productive oil wells, 64 net productive gas wells, and 102 net injection wells.

Since January 2, 2018, it had 0 insider buys, and 8 selling transactions for $10.98 million activity. The insider Vaughn Victor sold 60,000 shares worth $2.72 million. 20,000 shares were sold by Bhatt Padmanabh P., worth $960,716 on Monday, January 22. 50,000 shares were sold by PATRICK GREGORY S, worth $2.18 million.

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The company has market cap of $2.33 billion. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. It has a 42.09 P/E ratio. The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder ; and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD.

Permian Basin Royalty Trust (NYSE:PBT) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>